Immunological effects and therapeutic role of C5a in cancer

References

• Manthey H, Woodruff T, Taylor S, et al. Complement component 5a (C5a). Int J Biochem Cell Biol 2009;41:2114-17
   PubMed Web of Science ®Google Scholar
• Wetsel R, Lemons R, Le Beau M, et al. Molecular analysis of human complement component c5: localization of the structural gene to chromosome 9. Biochemistry 1988;27:1474-82
   PubMed Web of Science ®Google Scholar
• Vinay K, Abbas A, Aster J, et al. Robbins Basic Pathology. Elsevier Saunders; Philadelphia: 2013
   Google Scholar
• Kaufmann S, Rouse B, Sacks D. The Immune Response to Infection. ASM Press; Washington: 2011
   Google Scholar
• Bokisch V, Müller-Eberhard H. Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J Clin Invest 1970;49:2427-36
   PubMed Web of Science ®Google Scholar
• Monk P, Scola A, Madala P, et al. Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol 2007;152:429-48
   PubMed Web of Science ®Google Scholar
• Gao H, Neff T, Guo R, et al. Evidence for a functional role of the second C5a receptor C5L2. FASEB J 2005;19:1003-5
   PubMed Web of Science ®Google Scholar
• Higginbottom A, Cain S, Woodruff T, et al. Comparative agonist/antagonist responses in mutant human C5a receptors define the ligand binding site. J Biol Chem 2005;280:17831-40
   PubMedGoogle Scholar
• Huber-Lang M, Younkin E, Sarma J, et al. Generation of C5a by phagocytic cells. Am J Pathol 2002;161:1849-59
   PubMed Web of Science ®Google Scholar
• Huber-Lang M, Sarma J, Zetoune F, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006;12:682-7
   PubMed Web of Science ®Google Scholar
• Noris M, Remuzzi G. Overview of complement activation and regulation. Semin Nephrol 2013;33:479-92
   PubMed Web of Science ®Google Scholar
• Murphy K, Travers P, Walport M, et al. Janeway’s Immunobiology. Garland Science; New York: 2012
   Google Scholar
• Rossi V, Cseh S, Thielens N, et al. Interaction properties of human mannan-binding lectin (MBL)-associated serine proteases-1 and -2, MBL-associated protein 19, and MBL. J Immunol 2001;166:5068-77
   PubMedGoogle Scholar
• Hedstrom L. Serine protease mechanism and specificity. Chem Rev 2002;102:4501-24
   PubMed Web of Science ®Google Scholar
• Guo R, Ward P. Role of C5A in inflammatory responses. Annu Rev Immunol 2005;23:821-52
   PubMed Web of Science ®Google Scholar
• Kurihara R, Yamaoka K, Sawamukai N, et al. C5a Promotes migration, proliferation, and vessel formation in endothelial cells. Inflamm Res 2010;59:659-66
   PubMed Web of Science ®Google Scholar
• Ryan U. Endothelial Cells. CRC Press; FL: 1988
   Google Scholar
• Lacy P. Mechanisms of degranulation in neutrophils. Allergy Asthma Clin Immunol 2006;2:98-108
   PubMedGoogle Scholar
• Gunn L, Ding C, Liu M, et al. Opposing roles for complement component C5a in tumor progression and the tumor microenvironment. J Immunol 2012;189:2985-94
   Google Scholar
• Kim D, Martin C, Lee S, et al. Expression of complement protein C5a in a murine mammary cancer model: tumor regression by interference with the cell cycle. Cancer Immunol Immunother 2005;54:1026-37
   PubMedGoogle Scholar
• Lamagna C, Aurrand-Lions M, Imhof B. Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Bio 2006;80:705-13
   PubMedGoogle Scholar
• Chan C, Andrews D, Smyth M. Can NK Cells be a therapeutic target in human cancer? Eur J Immunol 2008;38:2964-8
   PubMed Web of Science ®Google Scholar
• Markiewski M, DeAngelis R, Benencia F, et al. Modulation of the antitumor immune response by complement. Nat Immunol 2008;9:1225-35
   PubMed Web of Science ®Google Scholar
• Corrales L, Ajona D, Rafail A, et al. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol 2012;189:4674-83
   PubMed Web of Science ®Google Scholar
• Hidetoshi N, Wada Y, Kawano Y, et al. Enhancement of human cancer cell motility and invasiveness by anaphylatoxin c5a via aberrantly expressed c5a receptor (CD88). Clin Cancer Res 2013;19:2004-13
   PubMedGoogle Scholar
• Lechner M, Liebertz D, Epstein A. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010;185:2273-84
   PubMed Web of Science ®Google Scholar
• Okusawa S, Dinarello C, Yancey K, et al. C5a induction of human interleukin 1. synergistic effect with endotoxin or interferon-gamma. J Immunol 1987;139:2635-40
   PubMed Web of Science ®Google Scholar
• Yang Li, DeBusk L, Fukuda K, et al. Expansion of myeloid immune suppressor gr+cd11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004;6:409-21
   PubMed Web of Science ®Google Scholar
• Melani C, Chiodoni C, Forni G, et al. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in C-erbB-2 Transgenic BALB/c Mice suppresses immune reactivity. Blood 2003;102:2138-45
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg S. Cancer and complement. Nat Biotechnol 2008;26:1348-9
   PubMed Web of Science ®Google Scholar
• Marx J. Cancer’s bulwark against immune attack: MDS cells. Science 2008;319:154-6
   PubMed Web of Science ®Google Scholar
• Corzo C, Cotter M, Cheng P, et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 2009;182:5693-701
   PubMed Web of Science ®Google Scholar
• Popovic P, Zeh H, Ochoa J. Arginine and immunity. J Nutr 2007;137:1681S-6S
   PubMed Web of Science ®Google Scholar
• Srivastava M, Sinha P, Clements V, et al. Myeloid-derived suppressor cells inhibit t-cell activation by depleting cystine and cysteine. Cancer Res 2010;70:68-77
   PubMed Web of Science ®Google Scholar
• Zetter B. Angiogenesis and tumor metastasis. Annu Rev Med 1998;49:407-24
   PubMed Web of Science ®Google Scholar
• Dvorak H. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. JClin Oncol 2002;20:4368-80
   PubMed Web of Science ®Google Scholar
• Chien M, Ku C, Johansson G. Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in Leukemic Cells via the VEGF-R3/JNK/AP-1 Pathway. Carcinogenesis 2009;30:2005-13
   PubMed Web of Science ®Google Scholar
• Brown L, Berse B, Jackman R, et al. Expression of vascularpermeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995;26:86-91
   PubMed Web of Science ®Google Scholar
• Guidi A, Abu-Jawdeh G, Berse B, et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 1995;87:1237-45
   PubMed Web of Science ®Google Scholar
• Wong M, Cheung N, Yuen S, et al. Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression. Int J Cancer 1999;81:845-50
   PubMed Web of Science ®Google Scholar
• Dvorak HF, Nagy JA, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999;237:97-132
   PubMed Web of Science ®Google Scholar
• Benjamin LE, Golijanin D, Itin A, et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159-65
   PubMed Web of Science ®Google Scholar
• Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990;172:1535-45
   PubMed Web of Science ®Google Scholar
• Nozaki M, Raisler BJ, Sakurai E. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci USA 2006;103:2328-33
   PubMed Web of Science ®Google Scholar
• Cortright D, Meade R, Waters S, et al. C5a, But Not C3a, Increases VEGF secretion in arpe-19 human retinal pigment epithelial cells. Curr Eye Res 2009;34(1):57-61
   PubMed Web of Science ®Google Scholar
• Martina B, Koraka P, Osterhaus A. Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev 2009;22:564-81
   PubMed Web of Science ®Google Scholar
• Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22
   PubMed Web of Science ®Google Scholar
• Martin D, Galisteo R, Gutkind J. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) Complex. J Biol Chem 2009;284:6038-42
   PubMed Web of Science ®Google Scholar
• Waugh D, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008;14:6735-41
   PubMed Web of Science ®Google Scholar
• Sternlicht M, Lochter A, Sympson CJ. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999;98:137-46
   PubMed Web of Science ®Google Scholar
• Overall C, López-Otín C. Strategies for Mmp inhibition in cancer: innovations for the Post-trial Era. Nat Rev Cancer 2002;2:657-72
   PubMed Web of Science ®Google Scholar
• Miyata Y, Iwata T, Maruta S, et al. Expression of matrix metalloproteinase-10 in renal cell carcinoma and its prognostic role. Eur Urol 2007;52:791-7
   PubMed Web of Science ®Google Scholar
• Justilien V, Regala R, Tseng I, et al. Matrix metalloproteinase-10 is required for lung cancer stem cell maintenance, tumor initiation and metastatic potential. PLoS One 2012;7(4):e35040
   PubMed Web of Science ®Google Scholar
• Murnan M, Cai J, Shuja S, et al. Active mmp-2 effectively identifies the presence of colorectal cancer. Int J Cancer 2009;125:2893-902
   PubMedGoogle Scholar
• Liu H, Kato Y, Erzinger S, et al. The role of MMP-1 in breast cancer growth and metastasis to the brain in a xenograft model. BMC Cancer 2012;12:583
   PubMedGoogle Scholar
• Coussens L, Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol 1996;3:895-904
   PubMed Web of Science ®Google Scholar
• Fini M, Cook J, Mohan R, et al. Matrix metalloproteinases. Academic Press; New York: 1998
   Google Scholar
• Kheradmand F, Werner E, Tremble P, et al. Role of Rac1 and oxygen radicals in collagenase-1 expression induced by cell shape change. Science 1998;280:898-902
   PubMed Web of Science ®Google Scholar
• Zwirner J, Fayyazi A, Gotze O. Expression of the anaphylatoxin C5a receptor in non-myeloid cells. Mol Immunol 1991;36:877-84
   Google Scholar
• Buchner R, Hugli T, Ember J, et al. Expression of functional receptors for human c5a anaphylatoxin (cd88) on the human hepatocellular carcinoma cell line hepg2. stimulation of acute-phase protein-specific mrna and protein synthesis by human c5a anaphylatoxin. J Immunol 1995;155:308-15
   PubMedGoogle Scholar
• Speidl W, Kastl S, Hutter R, et al. The complement component c5a is present in human coronary lesions in vivo and induces the expression of mmp-1 and mmp-9 in human macrophages in vitro. FASEB J 2011;25:35-44
   PubMedGoogle Scholar
• Rutkowski M, Sughrue M, Kane A, et al. Cancer and the complement cascade. Mol Cancer Res 2010;8:1453-65
   PubMed Web of Science ®Google Scholar
• Mukherjee P, Pasinetti G. Complement anaphylatoxin c5a neuroprotects through mitogen-activated protein kinase-dependent inhibition of caspase 3. J Neurochem 2001;77:43-9
   PubMed Web of Science ®Google Scholar
• Daveau M, Benard M, Scotte M, et al. Expression of a functional C5a receptor in regenerating hepatocytes and its involvement in a proliferative signaling pathway in rat. J Immunol 2004;173:3418-24
   PubMed Web of Science ®Google Scholar
• Cheng T, Chang M, Huang S. Overexpression of circulating c-met messenger rna is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer. Chest 2005;128:1453-60
   PubMed Web of Science ®Google Scholar
• Schindler R, Gefland J, Dinarello C. Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translational signal provided by lipopolysaccharide or IL-1 itself. Blood 1990;76:1631-8
   PubMed Web of Science ®Google Scholar
• Luo J, Maeda S, Hsu L, et al. Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNF-α to TRAIL-mediated tumor regression. Cancer Cell 2004;6:297-305
   PubMed Web of Science ®Google Scholar
• Apte R, Dotan S, Elkabets M, et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 2006;25:387-408
   PubMed Web of Science ®Google Scholar
• Markiewski M, DeAngelis R, Strey C, et al. The regulation of liver cell survival by complement. J Immunol 2009;182:5412-18
   PubMedGoogle Scholar
• Lin W, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007;117:1175-83
   PubMed Web of Science ®Google Scholar
• Floreani A, Gunselman S, Heires A, et al. Novel C5a agonist-based dendritic cell vaccine in a murine model of melanoma. Cell Cycle 2007;6:2835-9
   PubMed Web of Science ®Google Scholar
• Kollessery G, Nordgren T, Mittal A, et al. Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective c5a agonists ep54 and ep67 protect against aggressive large b cell lymphoma in a syngeneic murine model. Vaccine 2011;35:5904-10
   Google Scholar
• Rudilla F, Fayolle C, Cesares N, et al. Combination of a TLR4 ligand and anaphylatoxin c5a for the induction of antigen-specific cytotoxic t cell response. Vaccine 2012;30:2848-4858
   PubMedGoogle Scholar
• Nandakumar KS, Jansson A, Xu B, et al. A recombinant vaccine effectively induces c5a-specific neutralizing antibodies and prevents arthritis. PLoS One 2010;5(10):e13511
   Google Scholar
• Kessel C, Nandakumar KS, Peters FB, et al. A single functional group substitution in c5a breaks B cell and T cell tolerance and protects against experimental arthritis. Arthritis Rheumatol 2014;66(3):610-21
   PubMedGoogle Scholar
• Cavaco CK, Patras KA, Zlamal JE, et al. A novel C5a-derived immunobiotic peptide reduces Streptococcus agalactiae colonization through targeted bacterial killing. Antimicrob Agents Chemother 2013;57:5492-9
   PubMedGoogle Scholar